<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Angew Chem Int Ed Engl</journal-id><journal-id journal-id-type="iso-abbrev">Angew. Chem. Int. Ed. Engl</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1521-3773</journal-id><journal-id journal-id-type="publisher-id">ANIE</journal-id><journal-title-group><journal-title>Angewandte Chemie (International Ed. in English)</journal-title></journal-title-group><issn pub-type="ppub">1433-7851</issn><issn pub-type="epub">1521-3773</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5488172</article-id><article-id pub-id-type="doi">10.1002/anie.201702403</article-id><article-id pub-id-type="publisher-id">ANIE201702403</article-id><article-categories><subj-group subj-group-type="overline"><subject>Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Communications</subject><subj-group subj-group-type="heading"><subject>Ratiometric Sensors</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Bioluminescent Antibodies for Point‐of‐Care Diagnostics </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib id="anie201702403-cr-0001" contrib-type="author"><name><surname>Xue</surname><given-names>Lin</given-names><prefix>Dr.</prefix></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4540-3386</contrib-id><xref ref-type="aff" rid="anie201702403-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="anie201702403-cr-0002" contrib-type="author"><name><surname>Yu</surname><given-names>Qiuliyang</given-names></name><xref ref-type="aff" rid="anie201702403-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="anie201702403-cr-0003" contrib-type="author"><name><surname>Griss</surname><given-names>Rudolf</given-names><prefix>Dr.</prefix></name><xref ref-type="aff" rid="anie201702403-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="anie201702403-cr-0004" contrib-type="author"><name><surname>Schena</surname><given-names>Alberto</given-names><prefix>Dr.</prefix></name><xref ref-type="aff" rid="anie201702403-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="anie201702403-cr-0005" contrib-type="author" corresp="yes"><name><surname>Johnsson</surname><given-names>Kai</given-names><prefix>Prof.</prefix></name><address><email>kai.johnsson@mpimf-heidelberg.mpg.de</email></address><xref ref-type="aff" rid="anie201702403-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="anie201702403-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="anie201702403-aff-0001">
<label><sup>1</sup></label>
<institution>Ecole Polytechnique Fédérale de Lausanne (EPFL)</institution>
<named-content content-type="organisation-division">Institute of Chemical Sciences and Engineering (ISIC)</named-content>
<named-content content-type="organisation-division">NCCR in Chemical Biology</named-content>
<named-content content-type="post-code">1015</named-content>
<named-content content-type="city">Lausanne</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="anie201702403-aff-0002">
<label><sup>2</sup></label>
<institution>Lucentix SA</institution>
<named-content content-type="organisation-division">EPFL Innovation Park</named-content>
<named-content content-type="organisation-division">Bâtiment C</named-content>
<named-content content-type="post-code">1015</named-content>
<named-content content-type="city">Lausanne</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="anie201702403-aff-0003">
<label><sup>3</sup></label>
<institution>Max-Planck-Institute for Medical Research</institution>
<named-content content-type="organisation-division">Department of Chemical Biology</named-content>
<named-content content-type="post-code">69120</named-content>
<named-content content-type="city">Heidelberg</named-content>
<country country="DE">Germany</country>
</aff><pub-date pub-type="epub"><day>16</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><day>12</day><month>6</month><year>2017</year></pub-date><volume>56</volume><issue>25</issue><issue-id pub-id-type="doi">10.1002/anie.v56.25</issue-id><fpage>7112</fpage><lpage>7116</lpage><history><date date-type="received"><day>06</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>11</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2017 The Authors. Published by Wiley-VCH Verlag GmbH &amp; Co. KGaA.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution‐NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ANIE-56-7112.pdf"/><abstract><title><text><SENT sid="1" pm="."><plain>Abstract </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>We introduce a general method to transform antibodies into ratiometric, bioluminescent sensor proteins for the no‐wash quantification of analytes. </plain></SENT>
<SENT sid="3" pm="."><plain>Our approach is based on the genetic fusion of antibody fragments to NanoLuc luciferase and SNAP‐tag, the latter being labeled with a synthetic fluorescent competitor of the antigen. </plain></SENT>
<SENT sid="4" pm="."><plain>Binding of the antigen, here synthetic drugs, by the sensor displaces the tethered fluorescent competitor from the antibody and disrupts bioluminescent resonance energy transfer (BRET) between the luciferase and fluorophore. </plain></SENT>
<SENT sid="5" pm="."><plain>The semisynthetic sensors display a tunable response range (submicromolar to submillimolar) and large dynamic range (ΔR max&gt;500 %), and they permit the quantification of analytes through spotting of the samples onto paper followed by analysis with a digital camera. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author-generated"><kwd id="anie201702403-kwd-0001">antibodies</kwd><kwd id="anie201702403-kwd-0002">bioluminescence</kwd><kwd id="anie201702403-kwd-0003">point-of-care monitoring</kwd><kwd id="anie201702403-kwd-0004">sensors</kwd><kwd id="anie201702403-kwd-0005">therapeutic drug monitoring</kwd></kwd-group></SecTag><funding-group><award-group><funding-source>NCCR Chemical Biology</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Swiss National Science Foundation</funding-source></award-group></funding-group><funding-group><award-group><funding-source>École Polytechnique Fédérale de Lausanne</funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><ref-count count="26"/><page-count count="5"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>anie201702403</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 12, 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.2 mode:remove_FC converted:06.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="anie201702403-self">L. Xue, Q. Yu, R. Griss, A. Schena, K. Johnsson, <italic>Angew. Chem. Int. Ed.</italic>
<bold>2017</bold>, <italic>56</italic>, 7112.</mixed-citation>
</p></notes></front><body><p><text><SENT sid="6" pm="."><plain>The precise and reliable quantification of analytes in point‐of‐care (PoC) settings without the need for specialized instrumentation benefits public health in developed as well as developing countries. </plain></SENT>
<SENT sid="7" pm="."><plain>One of the challenges in the field is the development of generally applicable approaches to quantify drugs for PoC therapeutic drug monitoring (TDM).1 TDM is mostly based on mass‐spectrometry or antibody‐based immunoassays, both of which require specialized instrumentation or multiple assay steps, thus making their use for PoC applications by non‐expert users problematic.2, 3 Even though the generation of specific antibodies against various analytes is a routine procedure, approaches to transfer the specific binding of antibodies into a signal readout compatible with cheap and portable devices are needed. </plain></SENT>
</text></p><p><text><SENT sid="8" pm="."><plain>We recently introduced a new class of ratiometric and bioluminescent biosensors for PoC TDM.4 These luciferase‐based indicators of drugs (LUCIDs) are comprised of a SNAP‐tag, a blue‐emitting NanoLuc luciferase, and a binding protein for the drug of interest. </plain></SENT>
<SENT sid="9" pm="."><plain>SNAP‐tag is labeled with a molecule composed of a ligand for the binding protein and a red‐emitting fluorophore suitable for BRET.5, 6, 7 Binding of the drug by the sensor displaces the tethered fluorescent competitor from the binding protein, which disrupts bioluminescent resonance energy transfer (BRET) between the luciferase and the fluorophore and thus shifts the color from red to blue in a drug‐concentration‐dependent manner, thereby permitting the quantification of drugs by spotting samples onto paper, followed by analysis with a digital camera (Figure 1 a). </plain></SENT>
<SENT sid="10" pm="."><plain>However, up to now, no general strategy exists to identify suitable binding proteins. </plain></SENT>
<SENT sid="11" pm="."><plain>Here, we demonstrate how antibodies can be used as the binding proteins in LUCIDs, thereby establishing a general design principle for PoC‐compatible biosensors towards a basically unlimited number of analytes. </plain></SENT>
<SENT sid="12" pm="."><plain>Antibodies have three features that make them ideal binding proteins for LUCIDs: 1) all antibodies share a common three‐dimensional structure, which removes the need to optimize the sensor geometry for each individual senor; 2) the generation of antibodies against antigens of interest, including small molecules, is a routine procedure; 3) small‐molecule antigens need to be tethered to a carrier via a linker for antibody generation, thereby automatically providing a tethered ligand for sensor generation. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="13" pm="."><plain>The design of LUCIDs for PoC diagnostics. </plain></SENT>
<SENT sid="14" pm="."><plain>a) Schematic representation of the paper‐based device. </plain></SENT>
<SENT sid="15" pm="."><plain>The LUCID is a fusion protein of SNAP‐tag, NanoLuc luciferase (NLuc), and a binding protein (BP). </plain></SENT>
<SENT sid="16" pm="."><plain>SNAP‐tag is labeled with a molecule containing a fluorophore (red star) and a ligand (green ball) that binds to BP. </plain></SENT>
<SENT sid="17" pm="."><plain>The filter paper was printed with wax circles and the signal was collected by a digital camera. </plain></SENT>
<SENT sid="18" pm="."><plain>b) The variable fragment of the methotrexate antibody (PDB ID: 4OCX) bound to methotrexate (yellow). </plain></SENT>
<SENT sid="19" pm="."><plain>The N‐termini of both chains are indicated in green. </plain></SENT>
<SENT sid="20" pm="."><plain>The three CDRs (H1‐3, blue) on the heavy chain (light blue) and three CDRs (L1‐3, red) on the light chain (pink) are involved in antigen binding. </plain></SENT>
<SENT sid="21" pm="."><plain>c) In Fab‐based LUCIDs, the binding protein is an antibody Fab fragment. </plain></SENT>
<SENT sid="22" pm="."><plain>SNAP‐tag and NanoLuc are attached to the light chain. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-3" xlink:href="ANIE-56-7112-g001"/></fig><p><text><SENT sid="23" pm="."><plain>To generate antibody‐based LUCIDs, we focused on the antigen‐binding (Fab) fragment of antibodies. </plain></SENT>
<SENT sid="24" pm="."><plain>Fabs, which contain the complementary‐determining regions (CDRs) of antibodies, can be expressed as fusion proteins and are monovalent.8, 9, 10 The latter fact facilitates their use as LUCIDs. </plain></SENT>
<SENT sid="25" pm="."><plain>The N termini of both the heavy and light chains are in close proximity to the binding site, which should result in high BRET in the closed state of the biosensor (Figure 1 b). </plain></SENT>
<SENT sid="26" pm="."><plain>The CDR loop 3 of both chains are close to the respective N termini of each chain, but CDR H3s generally show much more variation in both length and space.11, 12, 13 In order to make the approach as general as possible, we therefore decided to attach SNAP‐tag and NanoLuc luciferase to the light chain of the Fab fragment (Figure 1 c). </plain></SENT>
<SENT sid="27" pm="."><plain>A rigid proline linker (Pro30) was introduced between SNAP‐tag and NanoLuc to lower the BRET efficiency in the open state of the sensor by increasing the distance between NanoLuc and the tethered fluorophore.14 We validated our design principle by generating Fab‐based sensor proteins for three distinct drugs, methotrexate, theophylline and quinine (Figure 2),15 and used the sensors for paper‐based PoC quantification of drug levels in human serum and blood samples. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="28" pm="."><plain>Antibody‐binding of methotrexate (a), theophylline (b), and quinine (c). </plain></SENT>
<SENT sid="29" pm="."><plain>The chemical structures of the three drugs are shown on the left. </plain></SENT>
<SENT sid="30" pm="."><plain>The crystal structures of antibodies with the methotrexate (PDB ID: 4OCX), theophylline derivative (PDB ID: 5BMF), and quinine (PDB ID: 4UIN) were superimposed, showing the interactions of the residues with the ligands (carbon atoms in green). </plain></SENT>
<SENT sid="31" pm="."><plain>Extensive hydrogen bonding (dotted orange lines) links the three antigens to the antibodies, either directly or via water molecules (red balls). </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-5" xlink:href="ANIE-56-7112-g002"/></fig><p><text><SENT sid="32" pm="."><plain>The response range of LUCIDs can be tuned by modifying the tethered ligand. </plain></SENT>
<SENT sid="33" pm="."><plain>When raising antibodies against small molecules, the affinity for the tethered molecule is usually higher than that for the free small molecule. </plain></SENT>
<SENT sid="34" pm="."><plain>The effective molarity of tethered ligands in our sensors can be estimated to be around 100 μm. </plain></SENT>
<SENT sid="35" pm="."><plain>Assuming that the same tethered molecule would be used for antibody and LUCID generation, the response range for antibody‐based LUCIDs would be more than 100 μm and therefore above the therapeutic concentration of most drugs. </plain></SENT>
<SENT sid="36" pm="."><plain>We show here how modification of the structure of the tethered ligand or mutagenesis of the antibody binding site permits lowering of the response range of LUCIDs to the nanomolar range. </plain></SENT>
<SENT sid="37" pm="."><plain>Taking advantage of structural information on the antibody–drug interactions (Figure 2),16, 17, 18 we prepared two tethered ligands for each sensor protein (Figure 3). </plain></SENT>
<SENT sid="38" pm="."><plain>For the methotrexate LUCID, we first decreased the picomolar binding affinity of the antibody towards methotrexate by introducing the mutation N36S on the heavy chain of the anti‐methotrexate Fab. </plain></SENT>
<SENT sid="39" pm="."><plain>The first tethered ligand (MTX1, Figure 3) for the methotrexate LUCID was then generated by attaching an ethylene glycol linker directly to 4‐amino‐4‐deoxy‐N‐methylpteroic acid (DAMPA), thereby removing hydrogen bonding between the glutamic acid of methotrexate and two asparagine residues of the antibody. </plain></SENT>
<SENT sid="40" pm="."><plain>For the second tethered ligand (MTX2), we also removed the methyl group to further decrease the binding affinity of the ligand. </plain></SENT>
<SENT sid="41" pm="."><plain>The anti‐theophylline Fab fragment binds to its antigen through several hydrogen bonds, including those between the amide bond on the linker and Tyr37 on the light chain and Arg53 on the heavy chain (Figure 2 b). </plain></SENT>
<SENT sid="42" pm="."><plain>Attaching a linker to N7 of theophylline (Theo1) or shifting the position of the amide bond (Theo2) should thus decrease the binding affinity of the tethered ligands (Figure 3). </plain></SENT>
<SENT sid="43" pm="."><plain>In the structure of anti‐quinine Fab fragment (Figure 2 c), the quinine interacts directly with Glu99 on the heavy chain and indirectly with Asn92 on the light chain of the Fab. </plain></SENT>
<SENT sid="44" pm="."><plain>Alkylation of the quinolinic or quinuclidinic nitrogen was thereby performed to yield the ligands Quin1 and Quin2 (Figure 3). </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="45" pm="."><plain>Molecules used for semisynthesis of the sensor proteins. </plain></SENT>
<SENT sid="46" pm="."><plain>The benzylguanine group serves as the reactive moiety for SNAP‐tag labeling (blue). </plain></SENT>
<SENT sid="47" pm="."><plain>The fluorophore Cy3 is colored in red. </plain></SENT>
<SENT sid="48" pm="."><plain>The ligands for different analytes are shown as R groups, which conjugate to the polyethylene glycol linker through amide bonds (green). </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-7" xlink:href="ANIE-56-7112-g003"/></fig><p><text><SENT sid="49" pm="."><plain>All of the sensor proteins were obtained through co‐expression of heavy and light chains from mammalian cells (Table S1 and Figure S1 in the Supporting Information). </plain></SENT>
<SENT sid="50" pm="."><plain>After labeling SNAP‐tag with the benzylguanine derivatives, the bioluminescence response of the resulting six LUCIDs in human serum was measured as a function of the corresponding analyte concentrations (Table 1). </plain></SENT>
<SENT sid="51" pm="."><plain>For all LUCIDs, titration with increasing concentrations of analyte led to a decrease in the emission of Cy3 and an increase in NanoLuc emission, which is in line with the free analyte displacing the tethered ligands (Figure 4 a–c and Figures S2–4). </plain></SENT>
<SENT sid="52" pm="."><plain>The maximal emission ratio changes (ΔR max) were all larger than 500 %, and up to 2155 % for the theophylline sensor Theo1‐Lucid (Table 1). </plain></SENT>
<SENT sid="53" pm="."><plain>To the best of our knowledge, this is the highest dynamic range for any BRET‐based ratiometric biosensor reported so far. </plain></SENT>
<SENT sid="54" pm="."><plain>For each sensor protein, tuning the binding affinities of the tethered ligands shifted the c50 values, defined as the analyte concentration that resulted in 50 % of the maximum ratio change, and permitted the detection of analyte levels from submicromolar to submillimolar concentrations (Table 1). </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="55" pm="."><plain>LUCIDs for methotrexate, theophylline, and quinine. </plain></SENT>
<SENT sid="56" pm="."><plain>Emission spectra of 5 nm MTX1‐Lucid (a), Theo1‐Lucid (b), and Quin2‐Lucid (c) in human serum spiked with known concentrations of the corresponding analyte. </plain></SENT>
<SENT sid="57" pm="."><plain>Emission ratios of methotrexate LUCIDs (d), theophylline LUCIDs (e), and quinine LUCIDs (f) as a function of analyte concentration. </plain></SENT>
<SENT sid="58" pm="."><plain>The measurements were performed on paper spotted with 5 μL sample (50 mm HEPES, 50 mm NaCl, pH 7.45, 50 % (v/v) serum, 1/100 furimazine). </plain></SENT>
<SENT sid="59" pm="."><plain>The data (mean±SD) are fitted to a single‐site binding isotherm (dashed line). </plain></SENT>
<SENT sid="60" pm="."><plain>Insets: pictures of the paper‐based devices in the detection of serum samples with the corresponding analytes (Top: LUCIDs with low c50 values; Bottom: LUCIDs with high c50 values). </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-9" xlink:href="ANIE-56-7112-g004"/></fig><SecTag type="TABLE"><table-wrap id="anie201702403-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="61" pm="."><plain>The ΔR max, c 50, and response range of the LUCIDs for the three drugs.[a] </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" span="1"/><col align="left" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>Sensor </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>ΔR max [%] </plain></SENT>
</text></th><th align="char" valign="top" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>c 50 [μm] </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>Response Range[b] </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>MTX1‐Lucid </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>1064 </plain></SENT>
</text></td><td align="char" valign="top" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>12.74±1.55 </plain></SENT>
</text></td><td rowspan="2" align="left" valign="top" colspan="1"><text><SENT sid="69" pm="."><plain>53 nm −0.13 mm </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>MTX2‐Lucid </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>863 </plain></SENT>
</text></td><td align="char" valign="top" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>0.53±0.05 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>Theo1‐Lucid </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>2155 </plain></SENT>
</text></td><td align="char" valign="top" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>92.96±5.02 </plain></SENT>
</text></td><td rowspan="2" align="left" valign="top" colspan="1"><text><SENT sid="76" pm="."><plain>0.84 μm −0.93 mm </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>Theo2‐Lucid </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>933 </plain></SENT>
</text></td><td align="char" valign="top" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>8.44±0.17 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>Quin1‐Lucid </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>562 </plain></SENT>
</text></td><td align="char" valign="top" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>4.87±0.90 </plain></SENT>
</text></td><td rowspan="2" align="left" valign="top" colspan="1"><text><SENT sid="83" pm="."><plain>0.49 μm −0.59 mm </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>Quin2‐Lucid </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>1036 </plain></SENT>
</text></td><td align="char" valign="top" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>59.12±8.51 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="anie201702403-tnote-0001"><p><text><SENT sid="87" pm="."><plain>[a] The measurements were performed in human serum (50 mm HEPES, 50 mm NaCl, pH 7.45, 50 % (v/v) serum) and the sensor concentration is 5 nm. </plain></SENT>
<SENT sid="88" pm="."><plain>[b] The response range represents the combined response ranges of two LUCIDs for each analyte. </plain></SENT>
</text></p></fn></table-wrap-foot><permissions><copyright-holder>Wiley‐VCH Verlag GmbH &amp; Co. KGaA</copyright-holder></permissions></table-wrap></SecTag><p><text><SENT sid="89" pm="."><plain>It is noteworthy that the high performance of the Fab‐based LUCIDs was achieved without any complex geometry optimization, such as circular permutation of the binding proteins, thus underlining the generality of the approach to transform the antibodies into bioluminescent sensors. </plain></SENT>
</text></p><p><text><SENT sid="90" pm="."><plain>Kinetic experiments showed that for all these sensors, the signal reached equilibrium within 15 min (Figure S5), thus making them suitable for rapid PoC testing. </plain></SENT>
<SENT sid="91" pm="."><plain>To evaluate the sensors for possible cross‐reactivity, we next titrated them with different potential drug metabolites or known interference compounds. </plain></SENT>
<SENT sid="92" pm="."><plain>7‐hydroxy methotrexate, which is the major metabolite of methotrexate,19 did not induce an obvious ratio response in either methotrexate sensor, while the minor metabolite 4‐amino‐4‐deoxy‐N‐ methylpteroic acid (DAMPA) showed a five‐fold larger c50 and should not interference with the detection of methotrexate (Figure S6).20 Key metabolites of theophylline and compounds structurally similar to theophylline, including 1,3‐dimethyluric acid, 1‐methylxanthine, and 3‐methylxanthine,21 did not interfere with the measurements of theophylline (using Theo1 as tethered ligand) in the therapeutic relevant concentration range of the drug (Figure S7). </plain></SENT>
<SENT sid="93" pm="."><plain>The key metabolite of quinine, 3‐hydroxyquinine,22 and other quinoline‐based antimalaria drugs commonly used in a combination with quinine for medical treatments, also showed negligible signal response, thus indicating that the quinine LUCIDs show excellent specificity (Figure S8). </plain></SENT>
<SENT sid="94" pm="."><plain>These data showed that the antibodies preserved their high specificity during the transformation into bioluminescent sensors. </plain></SENT>
</text></p><p><text><SENT sid="95" pm="."><plain>In order to transfer these antibody‐based biosensors into PoC devices suitable for easy, portable, and inexpensive diagnostics, we constructed paper‐based devices that allowed simple quantification with a digital camera.4 We therefore investigated whether the Fab‐based sensors would be compatible with measurements on paper. </plain></SENT>
<SENT sid="96" pm="."><plain>For this, we pretreated paper with bovine serum albumin and the non‐ionic detergent TWEEN 20 to reduce adsorption of the sensor and analytes, as well as to improve diffusion of the spotted liquid.23 The LUCIDs were then lyophilized on the pre‐treated paper for later use. </plain></SENT>
<SENT sid="97" pm="."><plain>Titrations with samples (5 μL each) on paper exhibited similar results to those observed in serum buffer (Table S2). </plain></SENT>
<SENT sid="98" pm="."><plain>Using a digital camera, the analyte‐dependent color transition from red to blue was also recorded (Figure 4 d–f, inset). </plain></SENT>
<SENT sid="99" pm="."><plain>When transferring the RGB pixel data of the pictures into the CIE1931 xy chromaticity diagram, which is an objective specification of the quality of a color regardless of its luminance, the analyte‐dependent color transitions displayed good linearity, confirming the color mixing of red and blue with different ratios (Figure S9).24, 25 The ratio values between the average intensity per pixel in the blue and red color channel were calculated according to the known method (Figure 4 d–f).4 The c50 values obtained by the camera‐based measurements agreed well with those measured by the microplate reader (Table S2), thus suggesting that the digital‐camera‐based testing was a reliable method to provide laboratory‐quality results for the quantification of drugs on paper with a minimal sample volume. </plain></SENT>
</text></p><p><text><SENT sid="100" pm="."><plain>We next spiked the three drugs in HEPES buffer and measured the concentrations using the paper‐based devices. </plain></SENT>
<SENT sid="101" pm="."><plain>By comparing the results to those obtained with a UV/Vis spectrophotometric method, we observed a very good correlation (R=0.994) between the results measured by the two methods (Figure 5). </plain></SENT>
<SENT sid="102" pm="."><plain>Furthermore, the LUCIDs also exhibited a very good average inter‐assay coefficient of variation of 14.8 %. </plain></SENT>
<SENT sid="103" pm="."><plain>The paper strips with the dried LUCIDs did not show a significant decrease in performance after 35 days of storage at room temperature (Table S2). </plain></SENT>
<SENT sid="104" pm="."><plain>These results clearly demonstrated the suitability of the paper‐based devices for PoC TDM. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p><text><SENT sid="105" pm="."><plain>Correlation of the results obtained for the spiked samples (black: theophylline, red: methotrexate, and blue: quinine) using a traditional UV/Vis spectrophotometric method and LUCID. </plain></SENT>
<SENT sid="106" pm="."><plain>The LUCID measurements were performed on paper by spotting 5 μL sample/serum mixture (50 mm HEPES, 50 mm NaCl, pH 7.45, 50 % (v/v) serum, 1/100 furimazine), and the UV/Vis measurements in HEPES buffer (50 mm HEPES, 50 mm NaCl, pH 7.45). </plain></SENT>
<SENT sid="107" pm="."><plain>Each LUCID measurement is given as the mean±SD of three independent measurements. </plain></SENT>
<SENT sid="108" pm="."><plain>Regression analysis yielded a Pearson correlation coefficient R=0.994. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-11" xlink:href="ANIE-56-7112-g005"/></fig><p><text><SENT sid="109" pm="."><plain>We further used our paper‐based devices for the analysis of whole‐blood samples. </plain></SENT>
<SENT sid="110" pm="."><plain>Blood components such as hemoglobin are known to interfere with luciferase‐based measurements.26 However, we found that a simple dilution of the blood into HEPES buffer (1/10) sufficiently removed this effect in our diagnostic scheme. </plain></SENT>
<SENT sid="111" pm="."><plain>We successfully set up calibration curves from the diluted blood samples (Figure S10) for all three drugs. </plain></SENT>
<SENT sid="112" pm="."><plain>For these experiments, we used the LUCIDs with smaller c50 values, since they are more suitable for the analysis of ten‐fold diluted samples. </plain></SENT>
<SENT sid="113" pm="."><plain>The good match of the c50 values with those observed from serum samples and high maximal ratio changes demonstrate that the paper‐based devices permit the direct PoC quantification of drugs in diluted blood samples. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>In summary, we devised a general approach to transform antibodies into bioluminescent sensor proteins for therapeutic drugs. </plain></SENT>
<SENT sid="115" pm="."><plain>The sensors show high specificity, a tunable response range, and a large dynamic range. </plain></SENT>
<SENT sid="116" pm="."><plain>On paper‐based devices, they permit the PoC quantification of drug levels in serum/blood by using a low‐cost digital camera. </plain></SENT>
<SENT sid="117" pm="."><plain>The generation of specific antibodies towards almost any molecule is a well‐established technique, and our work therefore establishes a general design principle for PoC therapeutic drug monitoring that should ultimately improve patient care and bring benefits to low‐resource locations. </plain></SENT>
</text></p><SecTag type="COMP_INT"><sec disp-level="2" id="anie201702403-sec-0003" sec-type="conflict-of-interest"><title><text><SENT sid="118" pm="."><plain>Conflict of interest </plain></SENT>
</text></title><p><text><SENT sid="119" pm="."><plain>The authors declare no conflict of interest. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="120" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data"><p><text><SENT sid="121" pm="."><plain>As a service to our authors and readers, this journal provides supporting information supplied by the authors. </plain></SENT>
<SENT sid="122" pm="."><plain>Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. </plain></SENT>
<SENT sid="123" pm="."><plain>Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. </plain></SENT>
</text></p></supplementary-material><supplementary-material content-type="local-data"><caption><p><text><SENT sid="124" pm="."><plain>Supplementary </plain></SENT>
</text></p></caption><media xlink:href="ANIE-56-7112-s001.pdf"><caption><p><text><SENT sid="125" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack id="anie201702403-sec-0002"><title>Acknowledgements</title><p><text4fund><text><SENT sid="126" pm="."><plain>This work was supported by funding from the Swiss National Science Foundation, the NCCR Chemical Biology, and EPFL. </plain></SENT>
<SENT sid="127" pm="."><plain>We thank Dr. David Hacker, Laurence Durrer, and Soraya Quinche for the help of protein expression. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><ref id="anie201702403-bib-0001"><text><SENT sid="128" pm="."><plain>1  B. Sanavio ,  S. Krol , Front. </plain></SENT>
<SENT sid="129" pm="."><plain>Bioeng. </plain></SENT>
<SENT sid="130" pm="."><plain>Biotechnol. 2015, 3, 20.25767794 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0002"><text><SENT sid="131" pm="."><plain>2  F. Saint-Marcoux ,  F.-L. Sauvage ,  P. Marquet , Anal. </plain></SENT>
<SENT sid="132" pm="."><plain>Bioanal. </plain></SENT>
<SENT sid="133" pm="."><plain>Chem. 2007, 388, 1327–1349.17520242 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0003"><text><SENT sid="134" pm="."><plain>3  A. Dasgupta ,  P. Datta , Handbook of Drug Monitoring Methods, Humana, Totowa, NJ, 2008, pp. 67–86. </plain></SENT>
</text></ref><ref id="anie201702403-bib-0004"><text><SENT sid="135" pm="."><plain>4  R. Griss ,  A. Schena ,  L. Reymond ,  L. Patiny ,  D. Werner ,  C. E. Tinberg ,  D. Baker ,  K. Johnsson , Nat. </plain></SENT>
<SENT sid="137" pm="."><plain>Chem. </plain></SENT>
<SENT sid="138" pm="."><plain>Biol. 2014, 10, 598–603.24907901 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0005"><text><SENT sid="139" pm="."><plain>5  R. Arts ,  I. den Hartog ,  S. E. Zijlema ,  V. Thijssen ,  S. H. </plain></SENT>
<SENT sid="142" pm="."><plain>E. van der Beelen ,  M. Merkx , Anal. </plain></SENT>
<SENT sid="143" pm="."><plain>Chem. 2016, 88, 4525–4532.27018236 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0006"><text><SENT sid="144" pm="."><plain>6  R. Arts ,  S. J. </plain></SENT>
<SENT sid="146" pm="."><plain>A. Aper ,  M. Merkx , Methods Enzymol. 2017, 589, 87–114.28336075 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0007"><text><SENT sid="147" pm="."><plain>7  J. Bacart ,  C. Corbel ,  R. Jockers ,  S. Bach ,  C. Couturier , Biotechnol. </plain></SENT>
<SENT sid="148" pm="."><plain>J. 2008, 3, 311–324.18228541 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0008"><text><SENT sid="149" pm="."><plain>8  Y. Zhao ,  L. Gutshall ,  H. Jiang ,  A. Baker ,  E. Beil ,  G. Obmolova ,  J. Carton ,  S. Taudte ,  B. Amegadzie , Protein Expression Purif. 2009, 67, 182–189. </plain></SENT>
</text></ref><ref id="anie201702403-bib-0009"><text><SENT sid="150" pm="."><plain>9  B. H. Biela ,  L. A. Khawli ,  P. Hu ,  A. L. Epstein , Cancer Biother. </plain></SENT>
<SENT sid="154" pm="."><plain>Radiopharm. 2003, 18, 339–353.12954121 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0010"><text><SENT sid="155" pm="."><plain>10  P. Holliger ,  P. J. Hudson , Nat. </plain></SENT>
<SENT sid="157" pm="."><plain>Biotechnol. 2005, 23, 1126–1136.16151406 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0011"><text><SENT sid="158" pm="."><plain>11  H. Shirai ,  A. Kidera ,  H. Nakamura , FEBS Lett. 1999, 455, 188–197.10428499 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0012"><text><SENT sid="159" pm="."><plain>12  C. Chothia ,  A. M. Lesk , J. Mol. </plain></SENT>
<SENT sid="162" pm="."><plain>Biol. 1987, 196, 901–917.3681981 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0013"><text><SENT sid="163" pm="."><plain>13  J. L. Xu ,  M. M. Davis , Immunity 2000, 13, 37–45.10933393 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0014"><text><SENT sid="166" pm="."><plain>14  M. A. Brun ,  R. Griss ,  L. Reymond ,  K.-T. Tan ,  J. Piguet ,  R. J. </plain></SENT>
<SENT sid="169" pm="."><plain>R. </plain></SENT>
<SENT sid="170" pm="."><plain>W. Peters ,  H. Vogel ,  K. Johnsson , J. Am. </plain></SENT>
<SENT sid="172" pm="."><plain>Chem. </plain></SENT>
<SENT sid="173" pm="."><plain>Soc. 2011, 133, 16235–16242.21879732 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0015"><text><SENT sid="174" pm="."><plain>15  M. Schulz ,  S. Iwersen-Bergmann ,  H. Andresen ,  A. Schmoldt , Crit. </plain></SENT>
<SENT sid="175" pm="."><plain>Care 2012, 16, R136.22770392 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0016"><text><SENT sid="176" pm="."><plain>16  S. Gayda ,  K. L. Longenecker ,  S. Manoj ,  R. A. Judge ,  S. C. Saldana ,  Q. Ruan ,  K. M. Swift ,  S. Y. Tetin , Biochemistry 2014, 53, 3719–3726.24832237 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0017"><text><SENT sid="182" pm="."><plain>17  A. Bujotzek ,  A. Fuchs ,  C. Qu ,  J. Benz ,  S. Klostermann ,  I. Antes ,  G. Georges , mAbs 2015, 7, 838–852.26176812 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0018"><text><SENT sid="183" pm="."><plain>18  J. Zhu ,  J. Zhu ,  D. W. Bougie ,  R. H. Aster ,  T. A. Springer , Blood 2015, 126, 2138–2145.26282540 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0019"><text><SENT sid="187" pm="."><plain>19  D. G. Johns ,  T. L. Loo , J. Pharm. </plain></SENT>
<SENT sid="191" pm="."><plain>Sci. 1967, 56, 356–359. </plain></SENT>
</text></ref><ref id="anie201702403-bib-0020"><text><SENT sid="192" pm="."><plain>20  R. C. Donehower ,  K. R. Hande ,  J. C. Drake ,  B. A. Chabner , Clin. </plain></SENT>
<SENT sid="197" pm="."><plain>Pharmacol. </plain></SENT>
<SENT sid="198" pm="."><plain>Ther. 1979, 26, 63–72.445963 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0021"><text><SENT sid="199" pm="."><plain>21  T. J. Haley , Drug Metab. </plain></SENT>
<SENT sid="201" pm="."><plain>Rev. 1983, 14, 295–335.6341027 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0022"><text><SENT sid="202" pm="."><plain>22  J. Heaton ,  N. Rahmioglu ,  K. R. Ahmadi ,  C. Legido-Quigley ,  N. W. Smith , J. Pharm. </plain></SENT>
<SENT sid="206" pm="."><plain>Biomed. </plain></SENT>
<SENT sid="207" pm="."><plain>Anal. 2011, 55, 494–499.21377309 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0023"><text><SENT sid="208" pm="."><plain>23  K. Pardee ,  A. A. Green ,  T. Ferrante ,  D. E. Cameron ,  A. DaleyKeyser ,  P. Yin ,  J. J. Collins , Cell 2014, 159, 940–954.25417167 </plain></SENT>
</text></ref><ref id="anie201702403-bib-0024"><text><SENT sid="212" pm="."><plain>24  Z. Mao ,  Z. Yang ,  Y. Mu ,  Y. Zhang ,  Y. F. Wang ,  Z. Chi ,  C. C. Lo ,  S. Liu ,  A. Lien ,  J. Xu , Angew. </plain></SENT>
<SENT sid="215" pm="."><plain>Chem. </plain></SENT>
<SENT sid="216" pm="."><plain>Int. </plain></SENT>
<SENT sid="217" pm="."><plain>Ed. 2015, 54, 6270–6273; Angew. </plain></SENT>
<SENT sid="218" pm="."><plain>Chem. 2015, 127, 6368–6371. </plain></SENT>
</text></ref><ref id="anie201702403-bib-0025"><text><SENT sid="219" pm="."><plain>25  D. Malacara , Color Vision and Colorimetry: Theory and Applications , 2nd ed., SPIE, Bellingham, WA, 2011. </plain></SENT>
</text></ref><ref id="anie201702403-bib-0026"><text><SENT sid="220" pm="."><plain>26  M. Colin ,  S. Moritz ,  H. Schneider ,  J. Capeau ,  C. Coutelle ,  M. C. Brahimi-Horn , Gene Ther. 2000, 7, 1333–1336.10918505 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
